Iztok Hozo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Iztok Hozo has a total of 232 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Djulbegovic
Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC
28 shared publications Benjamin Djulbegovic
Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
18 shared publicationsAmbuj Kumar
Comparative Effectiveness Research, University of South Florida, Tampa, FL, United States of America
10 shared publications- Athanasios Tsalatsanis
Office of Research, Research Methodology and Biostatistics Core, University of South Florida, Tampa, FL 33612, USA
9 shared publications B. Djulbegovic
Division of Evidence-based Medicine, Department of Internal Medicine, University of South Florida & H. Lee Moffitt Cancer Center & Research Institute
7 shared publications- Branko Miladinovic
Center for Evidence-Based Medicine and Health Outcomes Research University of South Florida Tampa, FL
6 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112397
Sample Size Determination for Decision-centered Pragmatic Trials
- 1 July 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112397
Open AccessSample Size Determination for Decision-centered Pragmatic Trials
- Open Access
- 30 September 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 188, 112004
Theory of clinical therapeutic progress: reconciling equipoise with fat-tailed (skewed) outcomes
- 30 September 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 188, 112004
Open AccessTheory of clinical therapeutic progress: reconciling equipoise with fat-tailed (skewed) outcomes
- Open Access
- 12 May 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 184, 111828
There is no upper limit on the maximum effect that can be detected in randomized trials
- 12 May 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 184, 111828
Open AccessThere is no upper limit on the maximum effect that can be detected in randomized trials
- Open Access
- 15 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (20) , 5426-5429
Biomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome
- 15 October 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (20) , 5426-5429
Open AccessBiomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome
- Open Access
- 25 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 3914-3916
Thrombophilia management calculator
Iztok Hozo, Benjamin Djulbegovic; Thrombophilia Management Calculator, Blood Advances, , bloodadvances.2024013463, https://doi.org/10.1182/bloodadvances.20 Iztok Hozo, Benjamin Djulbegovic; Thrombophilia Management Calculator, Blood Advances, , bloodadvances.2024013463, https://doi.org/10.1182/bloodadvances.20
- 25 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (15) , 3914-3916
Open AccessThrombophilia management calculator
Iztok Hozo, Benjamin Djulbegovic; Thrombophilia Management Calculator, Blood Advances, , bloodadvances.2024013463, https://doi.org/10.1182/bloodadvances.20 Iztok Hozo, Benjamin Djulbegovic; Thrombophilia Management Calculator, Blood Advances, , bloodadvances.2024013463, https://doi.org/10.1182/bloodadvances.20
- Open Access
- 9 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (13) , 3596-3606
Decision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines
Decision analysis can play an essential role in informing practice guidelines. The American Society of Hematology (ASH) thrombophilia guidelines have made a significant step forward in demonstrating how decision modeling integrated within Grading of Recommendations Assessment, Developing, and Evaluation (GRADE) methodology can advance the field of guideline development. Although the ASH model was transparent and understandable, it does, however, suffer from certain limitations that may have generated potentially wrong recommendations. That is, the panel considered 2 models separately: after 3 to 6 months of index venous thromboembolism (VTE), the panel compared thrombophilia testing (A) vs discontinuing anticoagulants (B) and testing (A) vs recommending indefinite anticoagulation to all patients (C), instead of considering all relevant options simultaneously (A vs B vs C). Our study aimed to avoid what we refer to as the omitted choice bias by integrating 2 ASH models into a single unifying threshold decision model. We analyzed 6 ASH panel's recommendations related to the testing for thrombophilia in settings of “provoked” vs “unprovoked” VTE and low vs high bleeding risk (total 12 recommendations). Our model disagreed with the ASH guideline panels’ recommendations in 4 of the 12 recommendations we considered. Considering all 3 options simultaneously, our model provided results that would have produced sounder recommendations for patient care. By revisiting the ASH guidelines methodology, we have not only improved the recommendations for thrombophilia but also provided a method that can be easily applied to other clinical problems and promises to improve the current guidelines’ methodology.
- 9 July 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (13) , 3596-3606
Open AccessDecision theoretical foundations of clinical practice guidelines: an extension of the ASH thrombophilia guidelines
Decision analysis can play an essential role in informing practice guidelines. The American Society of Hematology (ASH) thrombophilia guidelines have made a significant step forward in demonstrating how decision modeling integrated within Grading of Recommendations Assessment, Developing, and Evaluation (GRADE) methodology can advance the field of guideline development. Although the ASH model was transparent and understandable, it does, however, suffer from certain limitations that may have generated potentially wrong recommendations. That is, the panel considered 2 models separately: after 3 to 6 months of index venous thromboembolism (VTE), the panel compared thrombophilia testing (A) vs discontinuing anticoagulants (B) and testing (A) vs recommending indefinite anticoagulation to all patients (C), instead of considering all relevant options simultaneously (A vs B vs C). Our study aimed to avoid what we refer to as the omitted choice bias by integrating 2 ASH models into a single unifying threshold decision model. We analyzed 6 ASH panel's recommendations related to the testing for thrombophilia in settings of “provoked” vs “unprovoked” VTE and low vs high bleeding risk (total 12 recommendations). Our model disagreed with the ASH guideline panels’ recommendations in 4 of the 12 recommendations we considered. Considering all 3 options simultaneously, our model provided results that would have produced sounder recommendations for patient care. By revisiting the ASH guidelines methodology, we have not only improved the recommendations for thrombophilia but also provided a method that can be easily applied to other clinical problems and promises to improve the current guidelines’ methodology.
- Open Access
- 14 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3214-3224
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis
Current hospital venous thromboembolism (VTE) prophylaxis for medical patients is characterized by both underuse and overuse. The American Society of Hematology (ASH) has endorsed the use of risk assessment models (RAMs) as an approach to individualize VTE prophylaxis by balancing overuse (excessive risk of bleeding) and underuse (risk of avoidable VTE). ASH has endorsed IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) risk assessment models, the only RAMs to assess short-term bleeding and VTE risk in acutely ill medical inpatients. ASH, however, notes that no RAMs have been thoroughly analyzed for their effect on patient outcomes. We aimed to validate the IMPROVE models and adapt them into a simple, fast-and-frugal (FFT) decision tree to evaluate the impact of VTE prevention on health outcomes and costs. We used 3 methods: the “best evidence” from ASH guidelines, a “learning health system paradigm” combining guideline and real-world data from the Medical University of South Carolina (MUSC), and a “real-world data” approach based solely on MUSC data retrospectively extracted from electronic records. We found that the most effective VTE prevention strategy used the FFT decision tree based on an IMPROVE VTE score of ≥2 or ≥4 and a bleeding score of <7. This method could prevent 45% of unnecessary treatments, saving ∼$5 million annually for patients such as the MUSC cohort. We recommend integrating IMPROVE models into hospital electronic medical records as a point-of-care tool, thereby enhancing VTE prevention in hospitalized medical patients.
- 14 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3214-3224
Open AccessConverting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis
Current hospital venous thromboembolism (VTE) prophylaxis for medical patients is characterized by both underuse and overuse. The American Society of Hematology (ASH) has endorsed the use of risk assessment models (RAMs) as an approach to individualize VTE prophylaxis by balancing overuse (excessive risk of bleeding) and underuse (risk of avoidable VTE). ASH has endorsed IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) risk assessment models, the only RAMs to assess short-term bleeding and VTE risk in acutely ill medical inpatients. ASH, however, notes that no RAMs have been thoroughly analyzed for their effect on patient outcomes. We aimed to validate the IMPROVE models and adapt them into a simple, fast-and-frugal (FFT) decision tree to evaluate the impact of VTE prevention on health outcomes and costs. We used 3 methods: the “best evidence” from ASH guidelines, a “learning health system paradigm” combining guideline and real-world data from the Medical University of South Carolina (MUSC), and a “real-world data” approach based solely on MUSC data retrospectively extracted from electronic records. We found that the most effective VTE prevention strategy used the FFT decision tree based on an IMPROVE VTE score of ≥2 or ≥4 and a bleeding score of <7. This method could prevent 45% of unnecessary treatments, saving ∼$5 million annually for patients such as the MUSC cohort. We recommend integrating IMPROVE models into hospital electronic medical records as a point-of-care tool, thereby enhancing VTE prevention in hospitalized medical patients.
- Open Access
- 12 May 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 171, 111392
High certainty evidence is stable and trustworthy, whereas evidence of moderate or lower certainty may be equally prone to being unstable
- 12 May 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 171, 111392
Open AccessHigh certainty evidence is stable and trustworthy, whereas evidence of moderate or lower certainty may be equally prone to being unstable
- 25 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 145, 101-111
Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible
- 25 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 145, 101-111
Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible